Neurolief在Proliv™Rx获得FDA批准后，再获600万美元投资，为抗抑郁药反应不佳的患者扩大脑神经调节疗法的使用机会

Neurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to Antidepressants

PR Newswire 等信源发布 2026-03-30 19:30



可切换为仅中文







微信扫码分享